Demand surpasses supply of oxygen in UP amid raging COVID-19 second wave

State needs abour 800 tonnes a day, but has only 600-650 tonnes

US officials urge to override Gilead patent

Most of US state attorney generals want the government to use its march-in-rights to license remdesivir to others

Remdisivir shows no benefits on COVID-19 patients in first clinical trial

Lancet paper contradicts Gilead results on drug which claimed improvement in patients  

Remdesivir: Predatory pricing of an unproven drug

Gilead Science’s price for the remdesivir drug reveals a faulty patents system and skewed policies of the United States

WHO strongly recommends COVID-19 pill Paxlovid for high-risk populations

Paxlovid may prevent more hospitalisations than its alternatives

More global trials for 3 COVID-19 drugs: WHO

The 3 drugs — used to treat malaria, cancer and immune disorders — will be tested on thousands of volunteer patients across 600 …

COVID-19: All 4 repurposed drugs fail to show efficacy in WHO Solidarity Trial

The drugs failed to reduce mortality, hospitalisation stay and initiation of ventilation in admitted patients 

Why do we need to worry about antimicrobial resistance in the time of COVID-19?

As more and more antimicrobials are used to control the virus and the co-infections, this indiscriminate use will further increase AMR

Fatal bacterial infections may stem from COVID-19 therapies, AMR a concern: Study

Researchers have found that SARS-CoV-2 and bacteria in lungs may affect each other’s ability to cause damage and worsen the outcome in a …

The world needs pharmaceuticals from China and India to beat COVID-19

Chinese manufacturers make around 40% of all APIs used worldwide; China, India are the source of 75-80% of APIs imported to US

COVID-19: Centre doesn’t clarify basis for CDSCO authorising remdesivir

Government also does not provide clarity about whether remdesivir should be given to only severe patients

COVID-19: US FDA grants emergency authorisation for remdesivir

EUA doesn't equal final nod; China trial painted different picture